Adenovirus‐Specific T Cells in Adults Are Frequent, Cross‐Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus‐Vectored Vaccines

Human adenoviruses (HAdVs) cause diverse disease presentations as pathogens and are also used as viral vectors for vaccines and gene therapy products. Pre-existing adaptive immune responses to HAdV are known to influence symptom severity, viral clearance and the success of viral vectored products. Of note, approximately 50% of the UK's adult population has received at least one dose of a chimpanzee adenovirus vectored SARS-CoV-2 vaccine (ChAdOx1) since January 2021. We used FluoroSpot analysis to quantify the interferon-gamma (IFNγ) and interleukin-2 (IL2) responses of healthy blood donors to HAdV species A, B, C, D and F and chimpanzee adenovirus Y25, related to HAdV species E. We find that cellular immune responses to multiple species of human adenovirus are ubiquitous among healthy adult blood donors and that stimulating PBMC with whole hexon peptide libraries induces a significantly greater IFNγ and IL2 response than using selected peptide pools alone. We then compared the cellular immune responses of ChAdOx1 recipients and control donors using PBMC collected in 2021 and found that homotypic and heterotypic IFNγ responses were significantly boosted in ChAdOx1 recipients but not controls. Finally, we show that in PBMC derived from blood donors, IFNγ responses are made to both conserved and variable regions of the hexon protein. Future vaccination campaigns using adenoviral vectored vaccines will need to account for the pre-existing exposure of recipients to both circulating HAdVs and vaccines such as ChAdOx1, which convey polyfunctional antiviral T cell responses to even low seroprevalence HAdV types.

Authors

Institutions

Publication Details

Journal
Journal of Medical Virology
Published
2025-02-01
DOI
https://doi.org/10.1002/jmv.70222
Citations
2
Primary Topic
Virus-based gene therapy research
Type
article
Field-Weighted Citation Impact
3.63

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Adenovirus‐Specific T Cells in Adults Are Frequent, Cross‐Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus‐Vectored Vaccines

Charlotte J. Houldcroft, Charles N. Agoti, Arnold W. Lambisia, Benjamin A. Krishna et al.
2 citations
Journal of Medical Virology
Virus-based gene therapy research
3.63
article

Adenovirus‐Specific T Cells in Adults Are Frequent, Cross‐Reactive to Common Childhood Adenovirus Infections and Boosted by Adenovirus‐Vectored Vaccines

Charlotte J. Houldcroft, Charles N. Agoti, Arnold W. Lambisia, Benjamin A. Krishna, Benjamin J. Ravenhill, Jennifer P. Hoang, Rookmini Mukhopadhyay
article en
2 citations

Abstract

Human adenoviruses (HAdVs) cause diverse disease presentations as pathogens and are also used as viral vectors for vaccines and gene therapy products. Pre-existing adaptive immune responses to HAdV are known to influence symptom severity, viral clearance and the success of viral vectored products. Of note, approximately 50% of the UK's adult population has received at least one dose of a chimpanzee adenovirus vectored SARS-CoV-2 vaccine (ChAdOx1) since January 2021. We used FluoroSpot analysis to quantify the interferon-gamma (IFNγ) and interleukin-2 (IL2) responses of healthy blood donors to HAdV species A, B, C, D and F and chimpanzee adenovirus Y25, related to HAdV species E. We find that cellular immune responses to multiple species of human adenovirus are ubiquitous among healthy adult blood donors and that stimulating PBMC with whole hexon peptide libraries induces a significantly greater IFNγ and IL2 response than using selected peptide pools alone. We then compared the cellular immune responses of ChAdOx1 recipients and control donors using PBMC collected in 2021 and found that homotypic and heterotypic IFNγ responses were significantly boosted in ChAdOx1 recipients but not controls. Finally, we show that in PBMC derived from blood donors, IFNγ responses are made to both conserved and variable regions of the hexon protein. Future vaccination campaigns using adenoviral vectored vaccines will need to account for the pre-existing exposure of recipients to both circulating HAdVs and vaccines such as ChAdOx1, which convey polyfunctional antiviral T cell responses to even low seroprevalence HAdV types.

Journal of Medical VirologyVol. 97(2)
University of Cambridge (GB), Kenya Medical Research Institute (KE), Cambridge School (PT)
Alborada Trust, Wellcome Trust, National Institute for Health and Care Research
Good health and well-being
Openalex Percentile: Top 9%
Virus-based gene therapy research
3.63
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.